| Current Price | $2.79 | Mkt Cap | $1.3B |
|---|---|---|---|
| Open | $2.91 | P/E Ratio | 0.00 |
| Prev. Close | $2.95 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.78 - $2.96 | Volume | 1,581,387 |
| 52-Wk Range | $2.15 - $13.68 | Avg. Daily Vol. | 2,557,238 |
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, 23andMe's mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple Food and Drug Administration authorizations for genetic health risk reports. 23andMe has created the world's largest crowdsourced platform for genetic research, with 80% of its customers electing to participate.
| Current Price | $2.79 | Mkt Cap | $1.3B |
|---|---|---|---|
| Open | $2.91 | P/E Ratio | 0.00 |
| Prev. Close | $2.95 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.78 - $2.96 | Volume | 1,581,387 |
| 52-Wk Range | $2.15 - $13.68 | Avg. Daily Vol. | 2,557,238 |
The best Bull and Bear pitches based on recency and number of recommendations.
Seems like $5 is a good entry price for this stock. Should have much more upside from here going forward.
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about ME.
Recs
EnigmaDude
(41.89)
Submitted: 1/14/2022 2:16:05 PM :
Start Price:
$5.02
NASDAQ:ME Score:
-28.76
Seems like $5 is a good entry price for this stock. Should have much more upside from here going forward.
Recs
TMFJaguar
(21.85)
Submitted: 1/14/2022 1:51:35 PM :
Start Price:
$5.00
NASDAQ:ME Score:
-29.66
High risk because the core business doesn't generate positive cash flow. High reward because the company should have the highest quality genetic dataset around. With advancement in data analytics over the next 5 to 10 years, I don't see how this won't be valuable. At its current price, it's trading at around a $2.3 billion market cap with over $700 million in cash, substantial cushion and downside mitigation. Not a sure thing, but if a drug is a winner, this will likely be a multibagger.
Recs
RNInvestor
(< 20)
Submitted: 11/16/2021 7:29:03 AM :
Start Price:
$10.84
NASDAQ:ME Score:
-57.82
The pivot into the utilization of genetic data to create novel therapeutics is promising. In addition to the consumer business that is already in place drug approvals could significantly drive up revenue for very little cost to the company.
Find the members with the highest scoring picks in ME.
chammond55 (93.49) Score: +60.76
The Score Leader is the player with the highest score across all their picks in ME.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| elektragreen159 | 54.24 | 8/13/2021 |
|
5Y | $7.63 | -63.30% | -12.27% | +51.03 | 0 Comment | |
| Bigcaps19 | 92.60 | 1/14/2022 |
|
5Y | $4.99 | -43.83% | -15.18% | +28.66 | 0 Comment | |
| kkconway | 99.49 |
|
|
3W | $3.07 | -8.79% | -9.37% | -0.57 | 0 Comment | |
| TMFJoryko | 75.27 | 3/28/2022 |
|
5Y | $3.69 | -24.12% | -13.61% | -10.51 | 0 Comment | |
| tradingfool1 | 27.57 | 2/2/2022 |
|
5Y | $4.57 | -38.73% | -13.95% | -24.78 | 0 Comment | |
| Itsnottoolate | < 20 | 2/15/2022 |
|
5Y | $4.51 | -37.92% | -11.93% | -25.99 | 0 Comment | |
| Sonogoom | 92.51 | 1/21/2022 |
|
5Y | $4.58 | -38.86% | -11.69% | -27.18 | 0 Comment | |
| PAGEBOY2020 | 54.50 | 2/7/2022 |
|
3M | $4.74 | -40.93% | -13.06% | -27.87 | 0 Comment | |
| EnigmaDude | 41.89 | 1/14/2022 |
|
5Y | $5.02 | -44.20% | -15.44% | -28.76 | 1 Comment | |
| TMFJaguar | 21.85 | 1/18/2022 |
|
5Y | $5.00 | -43.94% | -14.28% | -29.66 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
